Octapharma is a global biopharmaceutical company focused on plasma-derived medicines and recombinant proteins. It develops and manufactures therapies addressing a range of diseases, with emphasis on plasma products, production processes, and rigorous quality and safety standards. The company conducts research and development across its locations worldwide and engages in patient engagement and scientific outreach through its annual reports and news stories. It positions itself as advancing human life through collaborations and a broad portfolio of therapies in multiple disease areas.
No recent news for this company.